ReviewHepatology international2020
New drugs for NAFLD: lessons from basic models to the clinic.
Review in Hepatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Orphan drug uttroside B impedes MASH progression and HCC development in experimental models.JHEP reports : innovation in hepatology · 2026Article
- The ubiquitin-proteasome system: A potential target for the MASLD.Acta pharmaceutica Sinica. B · 2025Review
- KYLO-0603, a novel liver-targeting, thyroid hormone receptor-β agonist for the inhibition of MASH progression.PloS one · 2025Article
- Hepatic Steatosis Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Artificial Intelligence.Diagnostics (Basel, Switzerland) · 2024Article
- Evaluating the Effects of Perinatal Exposures to BPSIP on Hepatic Cholesterol Metabolism in Female and Male Offspring ICR Mice.Environmental health perspectives · 2024Article
- Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis.Acta biochimica et biophysica Sinica · 2024Article
- A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: learning from clinical trials.Journal of endocrinological investigation · 2024Review
- Identification of commensal gut bacterial strains with lipogenic effects contributing to NAFLD in children.iScience · 2024Article
- Mechanisms of 5-HT receptor antagonists in the regulation of fibrosis in a 3D human liver spheroid model.Scientific reports · 2024Article
- Endpoints in NASH Clinical Trials: Are We Blind in One Eye?Metabolites · 2024Review
- Quantitative assessment of inflammation and evaluation of spatial heterogeneity for non-alcoholic fatty liver disease in mice based on iron-adjustive T1.Quantitative imaging in medicine and surgery · 2024Article
- Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase.Journal of translational medicine · 2023Article
- Hepatic transcriptome signatures in mice and humans with nonalcoholic fatty liver disease.Animal models and experimental medicine · 2023Article
- Integrative analysis of bulk and single-cell RNA sequencing data reveals distinct subtypes of MAFLD based on N1-methyladenosine regulator expression.Liver research (Beijing, China) · 2023Article
- Customized liver organoids as an advancedInternational journal of biological sciences · 2023Review
- Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models.Frontiers in medicine · 2023Article
- Integrated strategy of RNA-sequencing and network pharmacology for exploring the protective mechanism of Shen-Shi-Jiang-Zhuo formula in rat with non-alcoholic fatty liver disease.Pharmaceutical biology · 2022Article
- Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?Biology · 2022Review
- Modulating hepatic macrophages with annexin A1 in non-alcoholic steatohepatitis.Clinical science (London, England : 1979) · 2022Article
- Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug.Journal of advanced research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The term nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of increasingly harmful conditions ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) to liver fibrosis and end-stage cirrhosis. NAFLD is the currently most common form of chronic liver disease in both adults and children worldwide. As NAFLD evolves as a global pandemic alongside the still growing prevalence of metabolic syndrome, obesity, and diabetes, it is inevitable to develop effective counterstrategies. Over the last decades, great effort has been dedicated to the understanding of the pathogenesis of NAFLD. This includes the development of an array of models for NAFLD, ranging from advanced in vitro (primary cells, 3D cultures, biochip, spheroids, organoids) to in vivo rodent models (particularly in mice). Based on these approaches novel therapies have been proposed and subsequently evaluated for patients with advanced forms of NAFLD, in particular those with NASH and liver fibrosis or cirrhosis. In this review, we delineate the current understanding of disease pathophysiology and depict how novel therapeutic strategies aim to exploit these different mechanisms to ameliorate, treat, or stop progression of NASH. We also discuss obstacles and chances along the way from basic models to promising clinical treatment options.
Indexed as
Identifiers
31802390What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.